Corpus Intelligence IC Memo — BEVERLY HOSPITAL 2026-04-26 03:43 UTC
IC Memo — BEVERLY HOSPITAL
Investment Committee Memorandum | MA | 261 beds | Grade B | EBITDA uplift $30.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BEVERLY HOSPITAL

CCN 220033 | nan, MA | 261 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

BEVERLY HOSPITAL is a 261-bed suburban community hospital in nan, MA with $410.6M in net patient revenue and a -1.6% operating margin. The hospital serves a payer mix of 30.7% Medicare, 14.0% Medicaid, and 55.3% commercial.

Thesis: Undervalued. Our ML models identify $30.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -1.6% to 5.8% (+736bps).

Net Revenue HCRIS$410.6M
Current EBITDA COMPUTED$-6.5M
Operating Margin COMPUTED-1.6%
Occupancy HCRIS78.9%
Revenue / Bed COMPUTED$1.6M
Net-to-Gross HCRIS41.1%
Distress Probability ML45.3%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
37
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -1.6% places it above the state median. Among 37 size-comparable peers (130-522 beds), the median margin is -11.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (130-522), prioritizing same-state peers. 37 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BEVERLY HOSPITAL (Target)MA261$410.6M-1.6%
CHILDRENS HOSPITAL CORPORATIONMA485$1.59B-27.2%
BOSTON MEDICAL CENTERMA440$1.19B-50.0%
LAHEY CLINIC HOSPITAL INC.MA345$991.1M-4.2%
TUFTS MEDICAL CENTERMA385$819.5M-49.1%
SOUTH SHORE HOSPITALMA374$711.6M-12.0%
NEWTON WELLESLEY HOSPITALMA216$624.3M-4.7%
CAPE COD HOSPITALMA239$620.3M-1.3%
BERKSHIRE MEDICAL CENTERMA238$522.9M-12.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $30.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$8.6M+210bp18mo
Cost to Collect4.5%2.5%$8.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$8.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$5.0M+122bp9mo
Clean Claim Rate88.0%96.0%$263K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$8.6M
Cost to Collect
$8.2M
Denial Rate Reduction
$8.1M
A/R Days Reduction
$5.0M
Clean Claim Rate
$263K
Total EBITDA Uplift$30.2M
Current EBITDA$-6.5M
+ RCM Uplift+$30.2M
Pro Forma EBITDA$23.7M
Current Margin-1.6%
Pro Forma Margin5.8%
WC Released (1x)$15.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-10.1M$259.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-10.1M$281.7M0.00x-100.0%
Bull Case9.0x11.0x$-9.1M$378.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-9.1M$409.8M0.00x-100.0%
Bear Case11.0x10.0x$-11.1M$111.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-11.1M$118.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 37 hospitals with 130-522 beds
  • Same-state prioritization (n=38)
  • Comp margins: P25=-28.1% / P50=-11.3% / P75=-0.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.